Cambrex posts increase in profit sales

Cambrex posts increase in profit and sales

12:33 PM, 7th May 2011
Cambrex posts increase in profit and sales
Steven M Klosk, President and CEO, Cambrex.


EAST RUTHERFORD, US: Cambrex Corporation reports first quarter results for the period ended March 31, 2011. The sales increased by 9.8 per cent compared to first quarter of 2010. The EBITDA for the company was $ 11 million in the first quarter of 2011, an increase of 21.3 per cent compared to $ 9.1 million in the first quarter of 2010.

The first quarter sales of $ 61.7 million were 9.8 per cent higher than the first quarter of 2010. First quarter of 2011 gross margin increased to 28.3 per cent from 25.8 per cent during the first quarter of 2010, with foreign currency unfavorably impacting gross margin by 2.5 per cent in the first quarter of 2011. Gross margins were positively impacted by higher sales and production volumes and lower production costs, partially offset by lower pricing.

Operating profit increased to $ 5.3 million in the first quarter of 2011 from $ 3.7 million in the first quarter of 2010. The increase in operating profit was driven primarily by higher gross profits partially offset by higher operating expenses as described above.

Net interest expense decreased to $ 0.6 million in the first quarter of 2011 from $ 1.2 million in first quarter of 2010. This decrease is primarily due to the maturing of the company’s higher fixed interest rate swaps in October 2010. Income from continuing operations for the first quarter of 2011 was $ 2.9 million or $ 0.10 per share compared to $ 1.7 million or $ 0.06 per share in the first quarter of 2010.

“We are pleased with our first quarter performance with sales volumes significantly higher year over year. In addition to the increases in sales volumes for some of our larger custom manufacturing products, we continue to see strong orders for our generic APIs. Cambrex Zenara is off to a positive start and has been asked to increase production as part of their customer’s launch of a leading nicotine replacement therapy product in India,” said Steven M Klosk, President and Chief Executive Officer, Cambrex.

Further ahead, Cambrex continues to expect that sales for 2011, excluding the impact of foreign currency, will increase between 3 per cent and 7 per cent versus 2010 and that full year 2011 EBITDA will be between $ 43 and $ 49 million. For 2011, Cambrex Zenara is expected to have revenues in the low to mid single digit millions and a small EBITDA loss.

(C) WOC News




Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

Sasol appoints Fluor’s Constable as CEO; first external hire

  JOHANNESBURG, SOUTH AFRICA: Sasol Ltd appointed Fluor Corporation’s, David E Constable as Chief Executive Officer, the first time it has ...

Read more
Lanxess to hike polychloroprene rubber capacity, invests € 17 million

  LEVERKUSEN, GERMANY: Lanxess is investing € 17 million in the expansion of its production capacities for polychloroprene solid rubber. Th ...

Read more
Invista expands spandex fibre plant in Foshan, China

  The global fibre producer doubles capacity to 24,500 ton to meet growing regional demand for premium elastane fibres. FOSHAN, CHINA: Invista ...

Read more
Linde to build large hydrogen and synthesis gas plant in Chongqing

MUNICH, GERMANY: The Linde Group will build and operate a large hydrogen and synthesis gas plant in the Chongqing Chemical Park in Western China in a ...

Read more
LyondellBasell’s reports higher earnings on improved margins

  Net income of $ 660 million; diluted earnings per share of $ 1.15 Quarterly EBITDA of $ 1,402 million; 84 per cent increase from four quart ...

Read more
Perstorp restarts caprolactone plant after Force Majeure

PERSTORP, SWEDEN: An unexpected technical problem in Perstorp’s Capa, caprolactone monomer plant forced Perstorp to temporarily shut down prod ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X